Study confirms early elevated HIV infection risk in some step study participants who received vaccine; risk decreased over time
After about 18 months, risk level decreased to that of volunteers who received a placebo
SEATTLE - May 7, 2012 - A long-term follow-up analysis of participants in the Step Study, an international
HIV-vaccine trial, has confirmed that certain subgroups of male study participants were at higher risk of becoming infected after
receiving the experimental vaccine compared to those who received a placebo. The vaccine used in the study did not contain the
HIV virus, but it did contain HIV genes which were delivered to cells using a vector that employed a type of cold virus
known as adenovirus serotype 5 (Ad5).
Of the 1,836 men examined in this study, 172 became infected with HIV. Within 18 months of enrollment or one year after the last
vaccination, men who had neutralizing antibodies to Ad5 or who were uncircumcised, or both, had a two- to four-fold increased risk
of acquiring an HIV infection, according to findings published in the May 4 online edition issue of
the Journal of Infectious Disease
The Hutchinson Center grant was one of three announced today by the National Institute of Allergy and Infectious Diseases, part of the
National Institutes of Health, to fund research focused on developing strategies for eradicating HIV infection via
its Martin Delaney Collaboratory program.
However, the study also found that the risk level waned after about 18 months to be equal to that of volunteers who received a placebo.
Why this association occurred, what the biological mechanisms were and why the risk of infection lessened with time are unknown and require more study,
according to Ann Duerr, M.D., a member of the Vaccine and Infectious Disease Division of Fred Hutchinson Cancer Research Center, who led
the data analysis.
"There seems to be some kind of biologic phenomena that affects infection risk," she said.
The current study indicated that self-reported risk behaviors, such as unprotected sex, did not differ significantly between
the vaccine and placebo arms of the Step trial.
The research also confirmed there was no elevated risk of infection in vaccinated men who were circumcised and who were Ad 5
seronegative (men who had no neutralizing antibodies to the adenovirus vector used in the vaccine). An earlier interim analysis of the
Step Study data, done after immunizations in the vaccine trial were halted in 2007, also detected this relationship between Ad5
sero-status and vaccine-associated HIV risk. Today, only men who are circumcised and Ad5 seronegative are eligible to receive
experimental HIV vaccines that use the adenovirus serotype 5 as a biological delivery mechanism.
Duerr said scientists need a better understanding of what happened biologically to men who became infected, before those who
are uncircumcised or seropositive for Ad 5 are enrolled in future vaccine trials in which the adenovirus serotype 5 vector is used.
Ad 5 is used as a vector because it elicits a strong immune response by CD8 T cells. These cytotoxic T lymphocytes are thought
to be responsible for controlling HIV infection.
In the current study, researchers analyzed data from male Step Study participants who enrolled in a trial that provided follow-up for up to four years after they enrolled in the Step study, or until Dec. 31, 2009, whichever came first.
The Step Study enrolled 3,000 male and female volunteers in North and South America, the Caribbean and Australia between 2004
and 2007. Injections in the study were halted in September 2007 after researchers detected a lack of effectiveness by the vaccine to
prevent HIV acquisition or reduce HIV viral load in infected participants, and a higher-than-expected number of HIV infections in
certain subgroups of vaccinees.
In addition to Hutchinson Center researchers, scientists from the San Francisco Department of Public Health, University of
Washington, Emory University, Care Resource, Merck Research Laboratories and two Peruvian institutions co-authored the paper. The study
was funded by Merck Research Laboratories and the National Institutes of Health.
Note to media: Please contact Dean Forbes to schedule an interview with Duerr or to obtain a copy of the
paper "Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among
participants in a randomized trial of recombinant adenovirus HIV vaccine (Step study)."
###
Fred Hutchinson Cancer Research Center
At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to
prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless
pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please
visit www.fhcrc.org .
MEDIA CONTACT
Dean Forbes
Fred Hutchinson Cancer Research Center
(206) 667-2896
dforbes@fhcrc.org
Source: Fred Hutchinson Cancer Research Center
"Reproduced with permission - Fred Hutchinson Cancer Research Center "
Fred Hutchinson Cancer Research Center
|
